AlpVision was invited to speak at the 66th Seminar of the French Pharma Industry for Continued Education in Paris, June 30, 2009.

A.R.C. pharma, the organizer of the 66th Pharmaceutical Seminar for the French Pharma Industry called on AlpVision to speak about anti-counterfeiting solutions within the framework of the first ever “Counterfeiting” session proposed by the Seminar. AlpVision was the only supplier invited, due in particular to its announcement of a new medicinal tablet protection process achieved without additional marking and based on intrinsic characteristics created during production by tablet presses. During the French Pharma seminar, the difference between identification and traceability (ePedigree) on the one hand and the uncovering of counterfeited medicine produced by criminal organizations on the other hand were discussed.

Example of ID that will be mandatory by January 1st 2011 in France for all pharma products. Visible information is repeated in the 2D machine readable code (Datamatrix).

AlpVision hired new employees for testing and developing Krypsos™.

AlpVision has hired new highly qualified employees in order to further develop Krypsos™, the AlpVision’s ASP.Net based platform that already passed the severe software quality and security audits recognized by the pharmaceutical industry. They will be assigned to Quality Control and Testing, and to further develop the platform, especially to integrate Krypsos™ within existing Product Management Software and to develop extended functionalities. (http://www.alpvision.com/krypsos-online-authentication.html)

Krypsos™ brings full control to products’ manufacturers to manage their overt and covert security features as well as the various authentication processes attached to each group of products or production runs. Krypsos is FDA 21 CFR Part 11 compliant for medicines sold in the USA.

AlpVision presents its solutions for the first time at LabelExpo Europe and PackExpo USA.


Please email us at avinfo@alpvision.com to inform us of your attendance.

Feel free to give us your opinion on this newsletter or ask for more information via email to newsletter@alpvision.com with the mention “Newsletter July 15, 2009” in the subject field. In the next issue, with your permission we may publish your remarks or additional information you may supply to us, if we judge it to be of interest to all our readers.